| Literature DB >> 35875402 |
Mariam Ali Abdulmalik1, Mohamed Ghaith Al-Kuwari1, Ahmad Haj Bakri1, Samya Ahmad Al Abdulla1, Mujeeb Chettiyam Kandy1, Maha Yousef Abdulla1, John Michael Gibb1.
Abstract
BACKGROUND: In March 2020, Qatar started reporting increased numbers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (COVID-19). National preventive measures were implemented, and a testing plan was developed to respond to the pandemic with the Primary Health Care Corporation (PHCC) as the central element. PHCC is the main public primary healthcare provider in Qatar and it operates in 27 health centers with around 1.4 million registered individuals as of January 1, 2020. The latter population was distributed across four main nationality groups; Middle Eastern and North African (51.5%), Asian (41.2%), African (2.4%), and others (5.1%). At the primary healthcare level in Qatar, this study describes the epidemiological characteristics of individuals registered at PHCC who had contracted COVID-19 in 2020 during the first wave before the vaccination phase and examines the factors associated with the positivity rate.Entities:
Keywords: COVID-19; Epidemiology; Primary Health Care; Qatar
Year: 2022 PMID: 35875402 PMCID: PMC9275378 DOI: 10.5339/qmj.2022.23
Source DB: PubMed Journal: Qatar Med J ISSN: 0253-8253
Figure 1.Primary Health Care Corporation (PHCC)-registered population distributed by five-year age-group and sex as of December 31, 2020.Source: Strategy Planning and Health Intelligence. Primary Health Care Corporation. Doha. 2021
Characteristics of the swabbed persons at the PHCC health centers between March 11 and December 31, 2020
| Male n (%) | Female n (%) | Total n (%) | |
|
| |||
| Demography | |||
|
| |||
| Mean age, years (SD) | 32.3 (17.3) | 31.2 (16.4) | 31.9 (16.8) |
|
| |||
| Median age, years (IQR) | 32 (20–43) | 31 (21–41) | 32 (21–42) |
|
| |||
| 0–18 years | 43,181 (22.0) | 39,542 (21.7) | 82,723 (21.8) |
|
| |||
| 19–39 years | 90,399 (46.0) | 92,180 (50.5) | 182,579 (48.2) |
|
| |||
| 40–59 years | 49,376 (25.2) | 41,441 (22.7) | 90,817 (24.0) |
|
| |||
| 60+ years | 9,458 (5.2) | 13,627 (6.9) | 23,085 (6.1) |
|
| |||
| Nationality-grouped | |||
|
| |||
| Middle East and North African (MENA) | 115,293 (58,7) | 100,737 (55.2) | 216,030 (57.0) |
|
| |||
| Asian | 62,627 (31.9) | 60,661 (33.2) | 123,288 (32.5) |
|
| |||
| African | 3,810 (1.9) | 6,954 (3.8) | 10,764 (2.8) |
|
| |||
| Others | 14,853 (7.8) | 14,269 (7.6) | 29,122 (7.7) |
|
| |||
| Reason for swabbing | |||
|
| |||
| Clinical suspicion | 50,837 (28.9) | 51,507 (28.2) | 102,344 (27.0) |
|
| |||
| Individual request | 23,676 (12) | 20,937 (12.0) | 44,613 (11.8) |
|
| |||
| Survey | 24,692 (12.0) | 22,250 (11.5) | 46,942 (12.4) |
|
| |||
| Contact tracing | 15,530 (7.9) | 17,449 (9.6) | 32,979 (8.7) |
|
| |||
| Port of entry | 26,150 (13.3) | 24,321 (13.3) | 50,471 (13.3) |
|
| |||
| Healthcare routine check up | 3,345 (1.7) | 4,253 (2.3) | 7,598 (2.0) |
|
| |||
| Others-Not specified | 11,594 (5.9) | 10,772 (5.9) | 22,366 (5.9) |
|
| |||
| Missing | 27,614 (14.1) | 19,112 (10.5) | 46,726 (12.3) |
|
| |||
| Symptoms presentation | |||
|
| |||
| Symptomatic | 43,943 (26.1) | 45,482 (28.0) | 89,425 (27.0) |
|
| |||
| Asymptomatic | 124,163 (73.9) | 117,162 (72.0) | 241,325 (73.0) |
|
| |||
| Comorbidities | |||
|
| |||
| Diabetes mellitus | 23,321 (11.9) | 17,965 (9.8) | 41,286 (10.9) |
|
| |||
| Cardiovascular disease | 6,464 (3.3) | 2,379 (1.3) | 8,843 (2.3) |
|
| |||
| Hypertension | 24,689 (12.6) | 18,071 (9.9) | 42,760 (11.3) |
|
| |||
| Asthma/Chronic obstructive pulmonary disease (COPD) | 17,968 (9.1) | 16,169 (8.8) | 34,137 (9.0) |
|
| |||
| Dyslipidemia | 21,661 (11.0) | 17,134 (9.4) | 38,795 (10.2) |
|
| |||
Figure 2.Number of persons swabbed for COVID-19 at the PHCC health centers and positivity rate by month
Positivity rate by nationality-grouped, age-group, region and symptoms presentation
| Male n (%) | Female n (%) | Total n (%) | |
|
| |||
| Nationality-grouped | |||
|
| |||
| MENA | 12,999 (11.3) | 10,966 (10.9) | 23,965 (11.1) |
|
| |||
| Asian | 9,796 (15.7) | 7,325 (12.9) | 17,121 (13.9) |
|
| |||
| African | 431 (11.3) | 651 (9.4) | 1,082 (10.0) |
|
| |||
| Others | 949 (6.4) | 922 (6.5) | 1,871 (6.4) |
|
| |||
| Age-group | |||
|
| |||
| 0–18 Years | 4,236 (9.8) | 4139 (10.5) | 8,375 (10.1) |
|
| |||
| 19–39 Years | 12,205 (13.5) | 10,323 (11.2) | 22,528 (12.3) |
|
| |||
| 40–59 Years | 6,514 (13.9) | 4,603 (11.1) | 11,117 (12.2) |
|
| |||
| 60+ Years | 1220 (8.9) | 799 (8.4) | 2,019 (8.7) |
|
| |||
| Region | |||
|
| |||
| Central | 8,077 (12.1) | 6,875 (10,3) | 14,952 (11.2) |
|
| |||
| Northern | 8,700 (11.7) | 7,332 (11.1) | 16,032 (11.4) |
|
| |||
| Western | 7,398 (13.3) | 5,657 (11.3) | 13,055 (12.3) |
|
| |||
| Symptoms presentation | |||
|
| |||
| Asymptomatic | 6,108 (4.9) | 5,805 (4.9) | 11,913 (4.9) |
|
| |||
| Symptomatic | 8,308 (18.3) | 8,717 (19.8) | 17,025 (19.0) |
|
| |||
Factors associated with the positivity rate (multi regression model)
| Variable | OR | 95% CI | P value |
|
| |||
| Sex | |||
|
| |||
| Female (reference) | |||
|
| |||
| Male | 1.15 | 1.13–1.17 | < 0.001 |
|
| |||
| Age-group | |||
|
| |||
| 0–18 Years (reference) | |||
|
| |||
| 19–39 Years | 1.25 | 1.22–1.28 | < 0.001 |
|
| |||
| 40–59 Years | 1.24 | 1.20–1.28 | < 0.001 |
|
| |||
| 60+ Years | 0.85 | 0.81–0.90 | < 0.001 |
|
| |||
| Nationality-grouped | |||
|
| |||
| MENA (reference) | |||
|
| |||
| Asian | 1.29 | 1.27–1.32 | < 0.001 |
|
| |||
| African | 0.90 | 0.84–0.96 | < 0.001 |
|
| |||
| Others | 0.55 | 0.52–0.58 | < 0.001 |
|
| |||
| Symptoms presentation | |||
|
| |||
| Asymptomatic (reference) | |||
|
| |||
| Symptomatic | 4.52 | 4.42–4.64 | < 0.001 |
|
| |||